Juvaris BioTherapeutics, a Pleasanton, Calif. company developing vaccine products for influenza and pneumonia, said it has raised the first $6 million half of its first round of funding .
The financing comes from Kleiner Perkins, the well-known venture firm that has focused its investments in the pandemic area with its “Pandemic & Biodefense Fund.”
Juvaris said it will close the second part of its round in 120 days, and that the total raised will be $12 million.
The company is also pursuing immunotherapy products for Hepatitis B and Biodefense applications.
The funds permit the company to buy assets from Valentis.
The company’s statement is here.
(Story first published 1/9)
Tags: co:Juvaris-BioTherapeutics, co:Valentis, inv:Kleiner-Perkins-Caufield-&-Byers
Trackback URL
